Orca Bio to Present Clinical Data on TREGZI™ and Its Clinical Pipeline at the 14th Annual Meeting of the Society of Hematologic Oncology

▤ Summary

Orca Bio announced that three clinical data presentations and study updates were accepted for the Society of Hematologic Oncology annual meeting. The company will present new information on TREGZI, its recently approved precision-cell therapy for allogeneic transplant in adults with hematologic malignancies. It will also share preliminary data on Orca-Q and a phase 2 trial design for Orca-T in older patients with blood cancers. The announcement highlights Orca Bio’s commercial-stage position and ongoing clinical development across its cell therapy pipeline.

▦ Linked Companies